22,000 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, Holdings Channel reports. The firm bought 22,000 shares of the company’s stock, valued at approximately $1,097,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Signaturefd LLC grew its position in Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. Lake Hills Wealth Management LLC bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $277,000. Occidental Asset Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $305,000. Dakota Wealth Management bought a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $354,000. Finally, Fiduciary Alliance LLC raised its holdings in Hims & Hers Health by 120.4% in the 2nd quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company’s stock worth $5,446,000 after acquiring an additional 59,686 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $51.40 on Tuesday. The company has a market capitalization of $11.62 billion, a price-to-earnings ratio of 64.25, a PEG ratio of 3.39 and a beta of 2.25. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock’s 50-day simple moving average is $51.04 and its 200-day simple moving average is $49.21. Hims & Hers Health, Inc. has a 52 week low of $18.33 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same quarter in the prior year, the business posted $0.06 EPS. The business’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In related news, CEO Andrew Dudum sold 660,000 shares of the firm’s stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares of the company’s stock, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Patrick Harrison Carroll sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company’s stock, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,448,056 shares of company stock worth $75,139,240 over the last ninety days. 17.71% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on HIMS. Truist Financial decreased their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Hims & Hers Health in a report on Tuesday, October 14th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.